"L'Hôpital Privé du Confluent (nouveau nom des Nouvelles Cliniques Nantaises et du Centre Catherine de Sienne depuis 2016) est un établissement de santé pluridisciplinaire situé à Nantes, en Pays de la Loire. Il fait partie du Groupe Vivalto Santé, troisième acteur national de l'hospitalisation privée. L'établissement propose des activités de consultation et d'hospitalisation en court séjour de médecine, chirurgie, cancérologie et cardiologie. Cet établissement dispose d'un service d'urgences 24h/24. L'Hôpital Privé du Confluent rassemble 200 praticiens exerçant une cinquantaine de spécialités, et plus de 1 100 salariés. Il est régulièrement classé parmi les meilleurs établissements privés de France."

During the past decade, Centre Catherine de Sienne conducted 93 clinical trials. In the 10-year time frame, 93 clinical trials started and 29 clinical trials were completed, i.e. on average, 31.2% percent of trials that started reached the finish line to date. In the past 5 years, 35 clinical trials started and 11 clinical trials were completed. i.e. 31.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre Catherine de Sienne" #1 sponsor was "ARCAGY/ GINECO GROUP" with 19 trials, followed by "UNICANCER" with 12 trials sponsored, "Hoffmann-La Roche" with 11 trials sponsored, "Boston Scientific Corporation" with 10 trials sponsored and "Nantes University Hospital" with 10 trials sponsored. Other sponsors include 115 different institutions and companies that sponsored additional 82 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre Catherine de Sienne" #1 collaborator was "Merck Sharp & Dohme LLC" with 8 trials as a collaborator, "AstraZeneca" with 7 trials as a collaborator, "Hoffmann-La Roche" with 6 trials as a collaborator, "ARCAGY/ GINECO GROUP" with 5 trials as a collaborator and "Boston Scientific Corporation" with 3 trials as a collaborator. Other collaborators include 100 different institutions and companies that were collaborators in the rest 89 trials.

According to Clinical.Site data, the most researched conditions in "Centre Catherine de Sienne" are "Breast Cancer" (18 trials), "Heart Failure" (11 trials), "Ovarian Cancer" (11 trials), "Coronary Artery Disease" (5 trials) and "Prostate Cancer" (5 trials). Many other conditions were trialed in "Centre Catherine de Sienne" in a lesser frequency.

Most popular intervention types in "Centre Catherine de Sienne" are "Drug" (104 trials), "Device" (42 trials), "Other" (21 trials), "Procedure" (11 trials) and "Biological" (6 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (10 trials), "Placebo" (10 trials), "Carboplatin" (8 trials), "Bevacizumab" (7 trials) and "Docetaxel" (7 trials). Other intervention names were less common.

The vast majority of trials in "Centre Catherine de Sienne" are 120 trials for "All" genders, 53 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "Centre Catherine de Sienne". undefined are not yet recruiting, 39 are recruiting, 21 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 88 completed trials in Centre Catherine de Sienne, undefined suspended trials, and 19 terminated clinical trials to date.

Out of the total trials that were conducted in Centre Catherine de Sienne, 7 "Phase 1" clinical trials were conducted, 42 "Phase 2" clinical trials and 68 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 25 trials that are defined as “Not Applicable".